TransMedics Group (NASDAQ:TMDX) Trading Up 6.7%

Share on StockTwits

TransMedics Group Inc (NASDAQ:TMDX)’s stock price was up 6.7% during mid-day trading on Friday . The stock traded as high as $19.22 and last traded at $18.75, approximately 421,323 shares were traded during trading. An increase of 171% from the average daily volume of 155,448 shares. The stock had previously closed at $17.58.

Several analysts have issued reports on TMDX shares. Cowen cut their price target on TransMedics Group from $40.00 to $28.00 and set an “outperform” rating for the company in a report on Thursday, November 7th. Zacks Investment Research raised TransMedics Group from a “sell” rating to a “hold” rating in a research note on Saturday, November 9th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. TransMedics Group currently has an average rating of “Buy” and an average price target of $33.00.

The company has a debt-to-equity ratio of 0.54, a current ratio of 7.33 and a quick ratio of 6.61. The business has a 50 day moving average price of $18.31 and a two-hundred day moving average price of $22.51.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.39) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.47) by $0.08. The business had revenue of $7.21 million during the quarter, compared to the consensus estimate of $6.67 million. On average, research analysts forecast that TransMedics Group Inc will post -2.09 EPS for the current year.

In other TransMedics Group news, Director David Weill acquired 10,000 shares of the company’s stock in a transaction dated Monday, November 11th. The stock was purchased at an average price of $17.00 per share, with a total value of $170,000.00. Following the completion of the purchase, the director now directly owns 10,000 shares in the company, valued at approximately $170,000. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

A number of institutional investors have recently made changes to their positions in the stock. Zimmer Partners LP boosted its stake in TransMedics Group by 2.4% during the third quarter. Zimmer Partners LP now owns 551,284 shares of the company’s stock valued at $13,093,000 after buying an additional 12,759 shares during the last quarter. Boston Partners bought a new position in TransMedics Group during the third quarter valued at approximately $96,000. State Street Corp boosted its stake in TransMedics Group by 27.5% during the third quarter. State Street Corp now owns 105,847 shares of the company’s stock valued at $2,514,000 after buying an additional 22,806 shares during the last quarter. Roubaix Capital LLC boosted its stake in TransMedics Group by 24.8% during the third quarter. Roubaix Capital LLC now owns 213,581 shares of the company’s stock valued at $5,073,000 after buying an additional 42,408 shares during the last quarter. Finally, River & Mercantile Asset Management LLP bought a new position in TransMedics Group during the second quarter valued at approximately $714,000. 67.59% of the stock is owned by institutional investors.

About TransMedics Group (NASDAQ:TMDX)

TransMedics, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. The company offers Organ Care System (OCS), an integrated, compact, portable preservation technology that addresses unmet need for organs for transplantation.

See Also: How Does the Quiet Period Work?

Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with MarketBeat.com's FREE daily email newsletter.